US FDA explains post-market study requirements for approved medicines
This article was originally published in SRA
The US Food and Drug Administration has issued final guidance explaining how it is implementing its authority under the FDA Amendments Act of 2007 to require certain post-marketing studies and clinical trials for approved prescription drugs and biologics1,2.
You may also be interested in...
An ambitious action plan drawn by an EU task force, if implemented on a priority basis by the European Commission, could increase the EU’s capacity to advise on, assess and analyze big data.
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.